PBX3 has been reported to be over-expressed in prostate cancer [25], whilst FANCG belongs to a group of proteins known as the Fanconi anemia complementation family and has been reported to be important in DNA damage repair pathways [26]. This evidence concerns the gene PBX3 and prostate carcinoma.